A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

465

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: NNC0519-0130
DRUG: Placebo
DRUG: Semaglutide

Sponsor

Novo Nordisk A/S